Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 1,694 | 12,886 | 2,344 | 54,024 | 462 |
| Cost of Goods | 1,348 | 1,551 | 1,454 | 109 | N/A |
| Gross Profit | 346 | 11,335 | 890 | 53,915 | 462 |
| Operating Expenses | 174,372 | 177,500 | 150,843 | 148,039 | 167,966 |
| Operating Income | -173,678 | -165,614 | -149,499 | -94,015 | -167,504 |
| Interest Expense | 20,344 | 15,134 | 11,067 | 10,839 | 9,738 |
| Other Income | -7,308 | 28,466 | -450 | 2,780 | 6,160 |
| Pre-tax Income | -201,330 | -152,282 | -161,016 | -102,074 | -171,082 |
| Net Income Continuous | -201,330 | -152,282 | -161,016 | -102,074 | -171,082 |
| Minority Interests | -4,933 | -5,105 | -5,081 | -5,726 | -8,003 |
| Net Income | $-196,397 | $-147,177 | $-155,935 | $-96,348 | $-163,079 |
| EPS Basic Total Ops | -1.35 | -1.00 | -1.06 | -0.66 | -1.18 |
| EPS Basic Continuous Ops | -1.38 | -1.04 | -1.10 | -0.70 | -1.23 |
| EPS Diluted Total Ops | -1.35 | -1.00 | -1.06 | -0.66 | -1.18 |
| EPS Diluted Continuous Ops | -1.38 | -1.04 | -1.10 | -0.70 | -1.23 |
| EBITDA(a) | $-171,794 | $-164,088 | $-149,234 | $-90,529 | $-166,938 |